Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics, Inc. centers on allegations that the company misrepresented the clinical efficacy of its product SLK compared to traditional monoclonal antibodies, particularly BIMZELX, leading to significant investor losses [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that SLK and BIMZELX share the same molecular targets (interleukin-17, or IL-17), which undermines the claimed competitive advantage of SLK [3]. - Allegations include that MoonLake misrepresented the Nanobody structure's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa (HS) [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Investor Actions - Hagens Berman is actively advising investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and suffered substantial losses due to the alleged undisclosed trial flaws [4]. - The deadline for investors to move the Court for appointment as lead plaintiff in the securities class action lawsuit is December 15, 2025 [1][4]. Firm Background - Hagens Berman is a global plaintiffs' rights law firm that has secured over $2.9 billion in settlements for investors in similar cases [4][8].

PresentationWelcome, everyone. This is the ProPhase Labs Webinar. We'll be getting started in 3 minutes at a quarter after the hour. This is the ProPhase Labs Webinar with RedChip. We'll be started.Operator Thank you very much. Let us get started. Hi. This is Craig with RedChip Companies. Thank you for joining today's event with ProPhase Labs, which trades on the NASDAQ under the ticker PRPH. With us today, we have Ted Karkus, the Chairman and CEO of ProPhase. We will begin with a brief presentation in a mo ...

How to Add Us to Google News Sending You to Google News in 3 © SDI Productions / E+ via Getty Images Skip to content S&P 500 6,818.20 -0.01% Dow Jones 47,274.60 -0.08% Nasdaq 100 25,373.60 +0.03% Russell 2000 2,475.97 +0.05% FTSE 100 9,690.40 -0.25% Nikkei 225 49,465.00 -0.03% Investing Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock Quick Read ByJohn Seetoo Just now This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation ...

Bitcoin was trading around $85,500 at 4 p.m. ET, well off its overnight high of more than $91,300, and other major cryptocurrencies like Ethereum and Solana also sold off sharply. CHARLY TRIBALLEAU / AFP via Getty Images Close Major stock indexes pulled back as the final trading month of the year began, with shares of big tech and cryptocurrency-tied firms falling amid risk-off sentiment. The blue-chip Dow Jones Industrial Average, benchmark S&P 500, and tech-heavy Nasdaq closed down 0.9%, 0.5%, and 0.4 ...

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover losses for investors under the federal securities laws. What if I purchased Skye Bioscience securities?If you purchased Skye Bioscience securities during the Class Period and suff ...

Share Mountain Valley MD Confirms Positive Agrarius Agricultural Trial Results, Advancing Toward Commercialization MVMD has been working with a client-directed third-party agricultural partner, FARMATAC, in Brazil to assess the impact of the application of the Agrarius product on mature citrus orchards. FARMATAC has extensive experience designing and managing advanced citrus trials and has completed evaluations on two key varieties of oranges in mature orchards: Hamlin and Valencia. TORONTO--(BUSINESS WIRE) ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Accessibility StatementSkip Navigation SOURCE OSR Holdings BELLEVUE, Wash., Dec. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. This presentation will provide investors and analysts with an updated overview of OSR Holdings' diversified healthcare platforms and strategic growth initiatives. Virtual Presentat ...

PresentationLadies and gentlemen, thank you for joining us, and welcome to Belite Bio's Phase III DRAGON Topline Results Conference Call. [Operator Instructions] I will now hand the conference over to Nathan Mata. Please go ahead.Nathan L. MataChief Scientific Officer Welcome, everyone, to the webcast presentation of topline data from our 2-year Phase III trial of Tinlarebant in Stargardt disease. This pivotal trial is known as the DRAGON study and is the largest interventional trial ever conducted in adole ...

RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.The company is evolving beyond neurology and that is not reflected in market capitalization.Analyst Brian Abrahams on Monday wrote that Neumora is “positioning” itself well with a competitive early asset in an NLRP3 class demonstrating emerging promise across multiple large-market indications, including obesity and cardiometabolic disease.Data in 2026 “shoul ...